Genetic polymorphism can help physician choosing the best lung cancer chemotherapy

Background: Lung cancer is one of the most frequent malignancy with high mortality rate. Non small cell lung cancer (NSCLC) is the most common histological type, representing approximately the 85% of all lung cancers. Platinum-based chemotherapyis the standard of care in the first line treatment for patients with advanced or metastatic NSCLC not carrying a driver mutation. Despite the recent advances, the overall survival (OS) of patients receiving chemotherapy remains exiguous, of approximately 8-10 months, with an high rate of toxicities. The new direction in personalization of care is to guarantee the best treatment, both in terms of outcome, and toxicities control. Therefore, the aim of our study is to identify some markers associated with toxicity, through the analysis of genetic polymorphisms involved in drugs metabolism.